Research on blood flow and inflammation in heart failure with preserved ejection fraction

The role of MicrOVasculature and Inflammation in the development of Heart Failure with Preserved Ejection Fraction - MOVIE-HFpEF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58391

Enrollment

Registered

2025-10-06

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diastolic heart failure Heart failure with normal pumping function

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with suspicion of having HFpEF

Exclusion criteria

Exclusion criteria: Acute heart failure, significant epicardial disease

Design outcomes

Primary

Measure	Time frame
The primary objective is to investigate which inflammatory disturbances, both in the myocardium and in the circulation, are associated with structural and functional changes in the coronary microvasculature and myocardium in patients with HFpEF.	—

Secondary

Measure	Time frame
The secondary objectives are to determine:the relationship between  the activity and/or type of inflammation with cardiac fibrosisthe association of CMD with  cardiac fibrosisthe correlation of circulating inflammatory markers with in-situ myocardial inflammationof the association of epicardial adipose tissue with myocardial inflammation and CMD	—

Countries

Netherlands

Contacts

Public ContactE Lipsic

Universitair Medisch Centrum Groningen

e.lipsic@umcg.nl+31 50 3614474

Outcome results